{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["15"],"submitter":["Wang Y"],"pubmed_abstract":["<h4>Background</h4>The majority of patients with lung cancer exhibit drug resistance after anti-PD-1 immunotherapy, leading to shortened patient survival time. Previous studies have suggested an association between epigenetic abnormalities such as methylation and clinical response to anti-PD-1 immunotherapy, while the role of SUMOylation in resistance to anti-PD-1 antibody immunotherapy is still unclear.<h4>Methods</h4>Here, the mRNA expression of 15 SUMO machinery components in PBMC from lung cancer patients receiving anti-PD-1 immunotherapy were analyzed using real-time PCR. Base on the percentage change in mRNA levels, the relationship between the expression of SUMO machinery components and outcomes of anti-PD-1 immunotherapy, and the influencing factors of SUMOylation were evaluated. P"],"journal":["Frontiers in immunology"],"pagination":["1424393"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11357960"],"repository":["biostudies-literature"],"pubmed_title":["Dysregulated gene expression of SUMO machinery components induces the resistance to anti-PD-1 immunotherapy in lung cancer by upregulating the death of peripheral blood lymphocytes."],"pmcid":["PMC11357960"],"pubmed_authors":["Li Y","Xu P","Liu M","Huang J","Zhang Y","Sun C","Wang Y"],"additional_accession":[]},"is_claimable":false,"name":"Dysregulated gene expression of SUMO machinery components induces the resistance to anti-PD-1 immunotherapy in lung cancer by upregulating the death of peripheral blood lymphocytes.","description":"<h4>Background</h4>The majority of patients with lung cancer exhibit drug resistance after anti-PD-1 immunotherapy, leading to shortened patient survival time. Previous studies have suggested an association between epigenetic abnormalities such as methylation and clinical response to anti-PD-1 immunotherapy, while the role of SUMOylation in resistance to anti-PD-1 antibody immunotherapy is still unclear.<h4>Methods</h4>Here, the mRNA expression of 15 SUMO machinery components in PBMC from lung cancer patients receiving anti-PD-1 immunotherapy were analyzed using real-time PCR. Base on the percentage change in mRNA levels, the relationship between the expression of SUMO machinery components and outcomes of anti-PD-1 immunotherapy, and the influencing factors of SUMOylation were evaluated. P","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024","modification":"2025-05-29T22:19:07.538Z","creation":"2024-11-09T11:07:10.824Z"},"accession":"S-EPMC11357960","cross_references":{"pubmed":["39211047"],"doi":["10.3389/fimmu.2024.1424393"]}}